NCT01686165View on ClinicalTrials.gov

Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

February 9, 2016

Study Completion Date

November 9, 2017

Conditions
Anaplastic Large Cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell Lymphoma
Interventions
DRUG

belinostat

Given IV

BIOLOGICAL

rituximab

Given IV

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Given IV

Trial Locations (1)

85724-5024

University of Arizona Cancer Center, Tucson

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER

NCT01686165 - Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | Biotech Hunter | Biotech Hunter